|
|
|
| Changes of serum interleukin-8, interleukin-22 and tumor necrosis factor-α levels in patients with allergic rhinitis and their relationship with the severity of disease |
| TIAN Shuangshuang1 LI Qin2 |
1.Clinical Medicine School, Qingdao University, Shandong Province, Qingdao 266003, China;
2.Department of Otolaryngology, Head and Neck Surgery, Linyi People’s Hospital, Shandong Province, Linyi 276000, China |
|
|
|
Abstract Objective To investigate the changes of serum interleukin -8 (IL-8), IL-22 and tumor necrosis factor-α (TNF-α) levels in patients with allergic rhinitis and their relationship with the severity of disease. Methods Eighty patients with allergic rhinitis who diagnosed and treated in Clinical Medicine School, Qingdao University (“our hospital”for short) from January 2018 to December 2019 were selected as the case group. According to the degree of allergic rhinitis, they were divided into mild rhinitis group (31 cases) and moderate-severe rhinitis group (49 cases). All patients received Budesonide Aerosolized Suspension and Montelukast Sodium Tablets, and the treatment lasted for 12 weeks. Another 80 healthy volunteers in our hospital during the same period were selected as the control group. Serum IL-8, IL-22, and TNF-α levels between the case group and the control group were compared before treatment and 12 weeks after treatment. Serum IL-8, IL-22, TNF-α levels, and score for allergic rhinitis (SFAR) in patients with different degree of allergic rhinitis were compared and the correlation between serum IL-8, IL-22, TNF-α levels, and SFAR score were analyzed. Results Before treatment, IL-8, IL-22, and TNF-α levels in the case group were higher than those in the control group, and the differences were statistically significant (P < 0.05). After 12 weeks of treatment, serum IL-8, IL-22, and TNF-α levels in the case group were lower than those before treatment, and the differences were statistically significant (P < 0.05); there was no significant difference in serum IL-8, IL-22, and TNF-α levels between the case group and the control group (P > 0.05). Serum IL-8, IL-22, and TNF-α levels in moderate-severe rhinitis group were higher than those in mild rhinitis group, and the differences were statistically significant (P < 0.05). SFAR score in moderate-severe rhinitis group was higher than that in mild rhinitis group, and the difference was statistically significant (P < 0.05). Serum IL-8, IL-22 and TNF-α levels were positively correlated with SFAR score (r = 0.825, 0.737, 0.792, P < 0.05). Conclusion Serum IL-8, IL-22 and TNF-α levels in patients with allergic rhinitis are generally elevated, which can be used in the auxiliary diagnosis and disease assessment of allergic rhinitis in clinical practice.
|
|
|
|
|
|
[1] Bousquet J，Devillier P，Arnavielhe S，et al. Treatment of allergic rhinitis using mobile technology with real-world data：The MASK observational pilot study [J]. Allergy，2018，73（9）：1763-1774.
[2] Bousquet J，Devillier P，Anto JM，et al. Daily allergic multimorbidity in rhinitis using mobile technology：A novel concept of the MASK study [J]. Allergy，2018，73（8）：1622-1631.
[3] Wise SK，Lin SY，Toskala E，et al. International Consensus Statement on Allergy and Rhinology：Allergic Rhinitis [J]. Int Forum Allergy Rhinol，2018，8（2）：108-352.
[4] Gentile D，Bartholow A，Valovirta E，et al. Current and future directions in pediatric allergic rhinitis [J]. J Allergy Clin Immunol Pract，2013，1（3）：214-226.
[5] 王孟，郑铭，王向东，等.中国过敏性鼻炎流行病学研究进展[J].中国耳鼻咽喉头颈外科，2019，26（8）：415-420.
[6] 陈星，纪盈盈，程鹏，等.宁波地区变应性鼻炎流行病学调查研究[J].现代实用医学，2016，28（3）：377-379.
[7] 胡思洁，魏萍，寇巍，等.变应性鼻炎患病率及危险因素Meta分析[J].临床耳鼻咽喉头颈外科杂志，2017，31（19）：1485-1491.
[8] 黄义，陈仕虎，任丽君，等.鼻分泌物嗜酸细胞检测评价布地奈德喷鼻剂治疗变应性鼻炎疗效分析[J].检验医学与临床，2017，14（16）：2403-2407.
[9] 江树生，林广.孟鲁司特钠联合布地奈德治疗小儿咳嗽变异性哮喘的效果观察[J].中国当代医药，2015，22（20）：121-123.
[10] 高琦，林庆国.Th22和IL-22在呼吸道过敏性疾病发病机理中的作用[J].国际免疫学杂志，2019，42（5）：516-519.
[11] 中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组，中华医学会耳鼻咽喉头颈外科学分会鼻科学组.变应性鼻炎诊断和治疗指南（2015年，天津）[J].中华耳鼻咽喉头颈外科杂志，2016，51（1）：6-24.
[12] 焦雪芹，张志永.过敏性鼻炎评分量表（SFAR）与临床病程相关性研究[J].中国现代医生，2014，52（14）：136-137，140.
[13] 熊颖，张琼，袁琨.miR-103和miR-107表达水平与变应性鼻炎患病风险、疾病严重程度和炎症水平的关联分析[J].福建医科大学学报，2019，53（6）：376-381.
[14] 李聪.变应性鼻炎患者IL-1R8表达及其配体IL-37免疫调控作用的研究[D].重庆：重庆医科大学，2018.
[15] Tsilochristou O，Kyriakakou M，Ma-nolaraki I，et al. Detection of local allergic rhinitis in children with chronic，difficult-to-treat，non-allergic rhinitis using multiple nasal provocation tests [J]. Pediatr Allergy and Immunol，2019，30（3）：296-304.
[16] Hamizan AW，Rimmer J，Alvarado R，et al. Positive allergen reaction in allergic and nonallergic rhinitis：a systematic review [J]. Int Forum Allergy Rhinol，2017，7（9）：868-877.
[17] Khattiyawittayakun L，Seresirikachorn K，Chitsuthipakorn W，et al. Effects of double-dose intranasal corticosteroid for allergic rhinitis：a systematic review and meta-analysis [J]. Int Forum Allergy Rhinol，2019，9（1）：72-78.
[18] Devillier P，Molimard M，Ansolabehere X，et al. Immu-notherapy with grass pollen tablets reduces medication dispensing for allergic rhinitis and asthma：A retrospective database study in France [J]. Allergy，2019，74（7）：1317-1326.
[19] 刘丹.孟鲁司特钠联合布地奈德治疗儿童过敏性鼻炎临床效果[J].临床合理用药杂志，2020，13（34）：91-92.
[20] 王晓君，纪英，张莉，等.经鼻吸入布地奈德治疗变应性鼻炎并发支气管哮喘急性发作期49例临床研究[J].陕西医学杂志，2015，44（1）：88-90.
[21] 刘杰，彭程.布地奈德结合氯雷他定对过敏性鼻炎患者临床疗效及Th1/Th2细胞因子表达的影响[J].吉林医学，2021，42（2）：390-391.
[22] 黄榆岚，邓志华，高思敏，等.变应性鼻炎患者血清IL-17、IL-25及TNF-α水平表达及与病情严重程度的关系研究[J].现代生物医学进展，2019，19（5）：911-914.
[23] 陈彪，王爱萍，邹国忠.小儿过敏性鼻炎治疗前后免疫功能及相关炎症因子变化及其临床意义[J].现代实用医学，2020，32（9）：1151-1153.
[24] 刘爽，马文成，张贤英，等.过敏性鼻炎患者血清IL-8、IL-22及TNF-α水平的变化及其与病情严重程度的关系研究[J].现代生物医学进展，2020，20（9）：1716-1719，1777.
[25] 朱培颖.变应性鼻炎与肿瘤坏死因子α的关系及研究现状[J].全科护理，2010，8（36）：3363-3365.
[26] 治桂茹，白文栋.血清白细胞介素22和干扰素γ在持续性变应性鼻炎患者中的临床检测意义[J].实用医院临床杂志，2020，17（3）：140-142.
[27] 余滋中，付艳乔，李国义.变应性鼻炎患者血清IL-6、IL-17和TNF-α表达水平及意义[J].解放军预防医学杂志，2017，35（4）：369-370，373. |
|
|
|
